Core 1: Biospecimen and Translational Pathology Core

核心 1：生物样本和转化病理学核心

• 批准号: 10270229
• 负责人: Yen-Michael S. Hsu
• 金额: $ 27.28万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10270229
• 关键词: Biological; Biological Assay; Biological Response Modifier Therapy; Blood Banks; Blood Cells; Blood Circulation; Body Fluids; Cancer Center; Cells; Characteristics; Clinical; Clinical Informatics; Clinical Pathology; Clinical Research; Clinical Trials; Collaborations; Core Facility; Correlative Study; Cutaneous Melanoma; Data; Databases; Enrollment; Ensure; Environment; Evaluation; Funding; Genotype; Grant; Health Insurance Portability and Accountability Act; Human body; Image; Immune response; Immunofluorescence Immunologic; Immunologic Monitoring; Immunosuppressive Agents; Immunotherapy; Institutes; Laboratories; Lead; Link; Malignant Neoplasms; Medical center; Melanoma Cell; Metadata; Outcome; Pathologic; Pathologist; Pathology; Patients; Peripheral; Phenotype; Process; Protocols documentation; Recording of previous events; Research; Research Personnel; Research Project Grants; Resources; Role; Sampling; Services; Skin Cancer; Specimen; Specimen Handling; Squamous cell carcinoma; Standardization; System; Therapeutic Intervention; Time; Tissue Harvesting; Tissues; Translational Research; Triage; Tumor-Infiltrating Lymphocytes; Tumor-infiltrating immune cells; Universities; Update; Work; base; biobank; cancer immunotherapy; data de-identification; data sharing; design; digital; liquid crystal polymer; melanoma; nano-string; neoplasm registry; neoplastic cell; operation; programs; repository; success

Abstract: Core 1 Core 1 has the responsibility for the procurement, flow and delivery to the SPORE investigators of biological specimens (tissues, tumor cells, tumor-infiltrating immune cells and cells in the peripheral circulation) and for providing clinicopathological annotation for all subjects enrolled in the clinical trials. This is a critical responsibility that requires diverse expertise in specimen handling, pathology and data base operation. For this reason, the Core will be co-directed by Dr. Whiteside, who will lead the specimen biorepository efforts and Dr. Lucas, a pathologist, who will lead the annotation efforts. The two Co-Directors will be assisted by two Co- Investigators: Dr. Hartman with expertise in clinical informatics systems, and Dr. Karunamurthy, a dermatophatologist with expertise in melanoma and skin cancers. The Biorepository and Pathology Core is embedded in the Immunological Monitoring and Cell Products Laboratory (IMCPL), a shared core facility at the Hillman Cancer Center (HCC) with a history of distinguished service to the previous Melanoma and Skin Cancer SPORE and to cancer immunotherapy studies at the Pittsburgh Cancer Institute (now Hillman Cancer Center, HCC) over the past 33 years. In its role as Core 1 for the MSCP SPORE, the IMCPL will support the biotherapy-based research of all projects by performing project-specific serial accrual of specimens prior to, during and post therapeutic interventions. Core 1 will procure and process all body fluids and tissues harvested from melanoma patients enrolled in SPORE studies and provide immunopathological tissue evaluations, including multispectral analysis of tumor-infiltrating immune cells using Vectra Polaris multispectral immunofluorescence imaging and NanoString GeoMx Digital Spatial Profiling (DSP). Core 1 will also assist the SPORE investigators in implementing assays necessary for evaluation of immunologic responses to immune therapies. Core 1 will ensure that all samples it collects are accompanied by annotations that will permit linking laboratory analyses with clinical results. Data and annotations will be stored in the MSCP SPORE research database and will be updated and retrieved for research projects following established HIPAA protocols. We have a long history of collaboration with the MSCP SPORE investigators, and in the context of this SPORE Program, will be entirely dedicated to the support of the clinical and translational research in patients with melanoma or squamous cell carcinoma.

摘要：核心1 核心1负责采购、流动和向SPORE研究者交付生物 样本（组织、肿瘤细胞、肿瘤浸润免疫细胞和外周循环中的细胞）和 为所有入组临床试验的受试者提供临床病理学注释。这是一个关键 这一职责需要在标本处理、病理学和数据库操作方面的各种专业知识。为此 因此，核心将共同指导博士怀特塞德，谁将领导标本生物储存的努力和博士。 卢卡斯，一位病理学家，他将领导注释工作。两名共同主任将由两名共同主任协助工作， 研究者：Hartman博士，具有临床信息学系统方面的专业知识; Karunamurthy博士， 皮肤科医生，擅长黑色素瘤和皮肤癌。生物储存和病理学核心是 嵌入免疫监测和细胞产品实验室（IMCPL），这是一个共享的核心设施， 希尔曼癌症中心（HCC）具有卓越的服务历史，以前的黑色素瘤和皮肤 癌症孢子和癌症免疫治疗研究在匹兹堡癌症研究所（现希尔曼癌症 在过去的33年里，HCC中心。作为MSCP SPORE的核心1，IMCPL将支持 所有项目的基于生物疗法的研究，方法是在研究之前对样本进行项目特定的连续累积， 治疗期间和治疗后。核心1将采购和处理采集的所有体液和组织 来自SPORE研究中登记的黑素瘤患者并提供免疫病理学组织评价， 包括使用Vectra Polaris多光谱对肿瘤浸润免疫细胞进行多光谱分析 免疫荧光成像和NanoString GeoMx数字空间轮廓（DSP）。核心1也将协助 SPORE研究人员在实施必要的检测，以评估免疫应答， 治疗核心1将确保它收集的所有样本都附有允许链接的注释 实验室分析与临床结果。数据和注释将存储在MSCP SPORE研究中 数据库，并将更新和检索的研究项目后，建立健康保险和责任法案协议。我们 与MSCP SPORE调查人员有着悠久的合作历史，在此SPORE背景下， 计划，将完全致力于支持患者的临床和转化研究， 黑素瘤或鳞状细胞癌。